{"downloaded": true, "htmlmade": false, "full": {"id": "33577800", "source": "MED", "pmid": "33577800", "pmcid": "PMC7871775", "fullTextIdList": {"fullTextId": "PMC7871775"}, "doi": "10.1016/j.ahj.2021.02.001", "title": "Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study.", "authorString": "Capell WH, Barnathan ES, Piazza G, Spyropoulos AC, Hsia J, Bull S, Lipardi C, Sugarmann C, Suh E, Rao JP, Hiatt WR, Bonaca MP.", "authorList": {"author": [{"fullName": "Capell WH", "firstName": "Warren H", "lastName": "Capell", "initials": "WH", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "CPC Clinical Research, Aurora, CO; Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO. Electronic address: warren.capell@cuanschutz.edu."}}}, {"fullName": "Barnathan ES", "firstName": "Elliot S", "lastName": "Barnathan", "initials": "ES", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Janssen Research and Development LLC, Raritan, NJ."}}}, {"fullName": "Piazza G", "firstName": "Gregory", "lastName": "Piazza", "initials": "G", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA."}}}, {"fullName": "Spyropoulos AC", "firstName": "Alex C", "lastName": "Spyropoulos", "initials": "AC", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Huntington, NY; Institute for Health Innovation and Outcomes Research, Feinstein Institutes for Medical Research, Manhasset, NY; Department of Medicine, Northwell Health at Lenox Hill Hospital, New York, NY."}}}, {"fullName": "Hsia J", "firstName": "Judith", "lastName": "Hsia", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "CPC Clinical Research, Aurora, CO; Division of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO."}}}, {"fullName": "Bull S", "firstName": "Scott", "lastName": "Bull", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Janssen Research and Development LLC, Raritan, NJ."}}}, {"fullName": "Lipardi C", "firstName": "Concetta", "lastName": "Lipardi", "initials": "C", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Janssen Research and Development LLC, Raritan, NJ."}}}, {"fullName": "Sugarmann C", "firstName": "Chiara", "lastName": "Sugarmann", "initials": "C", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Janssen Research and Development LLC, Raritan, NJ."}}}, {"fullName": "Suh E", "firstName": "Eunyoung", "lastName": "Suh", "initials": "E", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Janssen Research and Development LLC, Raritan, NJ."}}}, {"fullName": "Rao JP", "firstName": "Jaya Prakash", "lastName": "Rao", "initials": "JP", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "REDCap Cloud, Encinitas, CA."}}}, {"fullName": "Hiatt WR", "firstName": "William R", "lastName": "Hiatt", "initials": "WR", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "CPC Clinical Research, Aurora, CO; Division of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO."}}}, {"fullName": "Bonaca MP", "firstName": "Marc P", "lastName": "Bonaca", "initials": "MP", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "CPC Clinical Research, Aurora, CO; Division of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO."}}}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"volume": "235", "journalIssueId": "3155962", "dateOfPublication": "2021 May", "monthOfPublication": "5", "yearOfPublication": "2021", "printPublicationDate": "2021-05-01", "journal": {"title": "American heart journal", "ISOAbbreviation": "Am Heart J", "medlineAbbreviation": "Am Heart J", "NLMid": "0370465", "ISSN": "0002-8703", "ESSN": "1097-6744"}}, "pubYear": "2021", "pageInfo": "12-23", "abstractText": "<h4>Background</h4>COVID-19 is associated with both venous and arterial thrombotic complications. While prophylactic anticoagulation is now widely recommended for hospitalized patients with COVID-19, the effectiveness and safety of thromboprophylaxis in outpatients with COVID-19 has not been established.<h4>Study design</h4>PREVENT-HD is a double-blind, placebo-controlled, pragmatic, event-driven phase 3 trial to evaluate the efficacy and safety of rivaroxaban in symptomatic outpatients with laboratory-confirmed COVID-19 at risk for thrombotic events, hospitalization, and death. Several challenges posed by the pandemic have necessitated innovative approaches to clinical trial design, start-up, and conduct. Participants are randomized in a 1:1 ratio, stratified by time from COVID-19 confirmation, to either rivaroxaban 10 mg once daily or placebo for 35 days. The primary efficacy end point is a composite of symptomatic venous thromboembolism, myocardial infarction, ischemic stroke, acute limb ischemia, non-central nervous system systemic embolization, all-cause hospitalization, and all-cause mortality. The primary safety end point is fatal and critical site bleeding according to the International Society on Thrombosis and Haemostasis definition. Enrollment began in August 2020 and is expected to enroll approximately 4,000 participants to yield the required number of end point events.<h4>Conclusions</h4>PREVENT-HD is a pragmatic trial evaluating the efficacy and safety of the direct oral anticoagulant rivaroxaban in the outpatient setting to reduce major venous and arterial thrombotic events, hospitalization, and mortality associated with COVID-19.", "affiliation": "CPC Clinical Research, Aurora, CO; Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO. Electronic address: warren.capell@cuanschutz.edu.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial Protocol", "Clinical Trial, Phase III", "research-article", "Multicenter Study", "Pragmatic Clinical Trial", "Journal Article"]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Extremities", "meshQualifierList": {"meshQualifier": {"abbreviation": "BS", "qualifierName": "blood supply", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Myocardial Infarction", "meshQualifierList": {"meshQualifier": {"abbreviation": "ET", "qualifierName": "etiology", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Thrombosis", "meshQualifierList": {"meshQualifier": [{"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}, {"abbreviation": "PC", "qualifierName": "prevention & control", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Ischemia", "meshQualifierList": {"meshQualifier": {"abbreviation": "ET", "qualifierName": "etiology", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Hemorrhage", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CI", "qualifierName": "chemically induced", "majorTopic_YN": "N"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Placebos", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "Y", "descriptorName": "Hospitalization"}, {"majorTopic_YN": "N", "descriptorName": "Cause of Death"}, {"majorTopic_YN": "N", "descriptorName": "Hospital Mortality"}, {"majorTopic_YN": "N", "descriptorName": "Double-Blind Method"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "Y", "descriptorName": "Outpatients"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Venous Thromboembolism", "meshQualifierList": {"meshQualifier": [{"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}, {"abbreviation": "PC", "qualifierName": "prevention & control", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Factor Xa Inhibitors", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Rivaroxaban", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "COVID-19", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CO", "qualifierName": "complications", "majorTopic_YN": "Y"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Ischemic Stroke", "meshQualifierList": {"meshQualifier": {"abbreviation": "ET", "qualifierName": "etiology", "majorTopic_YN": "N"}}}]}, "chemicalList": {"chemical": [{"name": "Placebos", "registryNumber": "0"}, {"name": "Factor Xa Inhibitors", "registryNumber": "0"}, {"name": "rivaroxaban", "registryNumber": "9NDF7JZ4M3"}]}, "subsetList": {"subset": [{"code": "AIM", "name": "Core clinical journals"}, {"code": "IM", "name": "Index Medicus"}]}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1016/j.ahj.2021.02.001"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC7871775"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC7871775?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "0", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2021-05-05", "dateOfCreation": "2021-02-12", "firstIndexDate": "2021-02-13", "fullTextReceivedDate": "2021-02-12", "dateOfRevision": "2021-05-05", "electronicPublicationDate": "2021-02-09", "firstPublicationDate": "2021-02-09"}, "htmllinks": "https://europepmc.org/articles/PMC7871775", "abstract": "<h4>Background</h4>COVID-19 is associated with both venous and arterial thrombotic complications. While prophylactic anticoagulation is now widely recommended for hospitalized patients with COVID-19, the effectiveness and safety of thromboprophylaxis in outpatients with COVID-19 has not been established.<h4>Study design</h4>PREVENT-HD is a double-blind, placebo-controlled, pragmatic, event-driven phase 3 trial to evaluate the efficacy and safety of rivaroxaban in symptomatic outpatients with laboratory-confirmed COVID-19 at risk for thrombotic events, hospitalization, and death. Several challenges posed by the pandemic have necessitated innovative approaches to clinical trial design, start-up, and conduct. Participants are randomized in a 1:1 ratio, stratified by time from COVID-19 confirmation, to either rivaroxaban 10 mg once daily or placebo for 35 days. The primary efficacy end point is a composite of symptomatic venous thromboembolism, myocardial infarction, ischemic stroke, acute limb ischemia, non-central nervous system systemic embolization, all-cause hospitalization, and all-cause mortality. The primary safety end point is fatal and critical site bleeding according to the International Society on Thrombosis and Haemostasis definition. Enrollment began in August 2020 and is expected to enroll approximately 4,000 participants to yield the required number of end point events.<h4>Conclusions</h4>PREVENT-HD is a pragmatic trial evaluating the efficacy and safety of the direct oral anticoagulant rivaroxaban in the outpatient setting to reduce major venous and arterial thrombotic events, hospitalization, and mortality associated with COVID-19.", "pdflinks": "https://europepmc.org/articles/PMC7871775?pdf=render", "journaltitle": "American heart journal", "authorinfo": ["Capell WH", "Barnathan ES", "Piazza G", "Spyropoulos AC", "Hsia J", "Bull S", "Lipardi C", "Sugarmann C", "Suh E", "Rao JP", "Hiatt WR", "Bonaca MP"], "title": "Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study."}